Alternatively, VRK1 inhibition could emerge as a novel therapeutic target because it may facilitate the accumulation of toxic ROS in tumor cells in combination with other cancer drugs through the impairment of chromatin remodeling, resulting in decreased tumor cell viability and death. Here, VRK1 is linked to cancer.